The major depressive disorder (MDD) treatment market is forecasted to develop at a CAGR of 2.8% to reach US$ 14.96 billion market size by 2032 from its expected value of US$ 11.51 billion in 2022.
Major Depressive Disorder (MDD) Treatment Market Value (2022)
US$ 11.51 Mn
Major Depressive Disorder (MDD) Treatment Market Anticipated Value (2032)
US$ 14.96 Mn
Major Depressive Disorder (MDD) Treatment Market Growth Rate (2022-2032)
Clinical depression, sometimes referred to as major depressive disorder (MDD), is a mental health condition that affects mood, behavior, appetite, and sleep. Although the precise origin of MDD is unknown, there are a number of things that can increase one's chance of developing it, including a combination of genes and stress that alters brain chemistry and lowers one's capacity to keep their mood stable. MDD may also be brought on by hormonal imbalance, drug or alcohol misuse, certain illnesses like cancer or hypothyroidism, or unfavorable drug side effects like steroids.
The prevalence of MDD has increased as a result of evolving lifestyles, such as increased job pressure and alcohol addiction, which is anticipated to fuel market expansion over the forecast period. For instance, according to a 2015 published article in the National Center for Biotechnology Information, MDD is the most prevalent psychiatric condition in India, with lifetime prevalence rates of between 10 and 25 percent for women and between 5 and 12 percent for males.
An important factor driving the global Major Depressive Disorder (MDD) Market is the increased demand for therapeutic solutions for the medical treatment of MDD. The introduction of novel medications and increased pharmaceutical R&D spending have both contributed to this market's expansion. The continual development of medications with qualities like improved safety and high patient compliance is also fostering the expansion of the global market for major depressive disorder (MDD). The industry can increase significantly with the help of therapies like meditation, physiotherapy, and biological therapy.
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression.
The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing number of patients suffering from MDD has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The total market expansion will be constrained by a few obstacles and limitations. The development of the global market for treatments of major depressive disorder (MDD) is hampered by strict regulations imposed by numerous governments.
Additionally, the market's expansion has been constrained by the patent expirations of several popular medications and the ambiguity surrounding the negative effects of antidepressants. However, the ongoing advancements in technology, expanding medication manufacturing company mergers and acquisitions, quick product introductions, and untapped potential in emerging markets present attractive growth chances.
The market for treating major depressive disorder (MDD) is anticipated to develop as a result of regulatory agencies like the European Commission and the United States Food and Drug Administration, which are quickly approving new treatments.
Additionally, rising MDD prevalence, particularly in North America, is anticipated to fuel the market for treating major depressive disorder (MDD). One of the most prevalent mental health conditions in the US is MDD. For instance, MDD affects more than 16.1 million American adults, or roughly 6.7% of the population of the United States, who are 18 years of age and older, based on the Anxiety and Depression Association of America (ADAA).
Growing geriatric populations and increased knowledge of different depressive episodes are predicted to provide market participants with lucrative growth prospects. An aging population, rising major depressive disorder incidence, and developments in the antidepressant drug industry are all contributing to the growth of the Major Depressive Disorder (MDD) Market.
A major influencer of worldwide health is the rise in the number of people suffering from depression. The World Health Organization estimates that 264 million people worldwide suffer from depression. Worldwide, depression is a major contributor to the burden of disease and a major cause of disability.
The major depressive disorder epidemiology division offers information on the patient pool's past, present, and anticipated trends for each of the world's seven major nations. Examining various research and the opinions of influential people assists in identifying the reasons for present and anticipated trends.
The market for treating the major depressive disorder is undergoing a dynamic transformation since patents on medications like Cymbalta and Abilify have recently expired, and sales of these products have fallen sharply since generic versions of these medications entered the market. Therefore, a key factor in the growth of this industry is the approval of new medications like Levomilnacipran, Brintellix, and Rexulti (brexpiprazole). In 2013, the FDA approved the novel SNRI levomilnacipran for the treatment of the major depressive disorder (MDD) in adults.
The FDA approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder, according to an announcement from Takeda Pharmaceutical Company Limited and H. Lundbeck A/S. (MDD). In July 2015, the FDA approved the use of Rexulti (brexpiprazole) tablets as an additional therapy for people with major depressive disorder (MDD). These approvals are anticipated to give MDD sufferers more options, which is anticipated to assist the expansion of the market for treating the condition.
The key reasons propelling the growth of the global Major Depressive Disorder (MDD) Market are the rising demand for antidepressants as a result of the imbalance in work life and different lifestyles. Another aspect that contributed to the market's progress was the businesses' cooperation in the development of new pharmaceuticals. The market is comprehensively evaluated in the study on the global major depressive disorder (MDD) market. The research provides a thorough analysis of the market's key segments, trends, drivers, restraints, competitive environment, and other important elements.
Work life imbalances due to change in life style, and increase in MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among the drug manufactures across the globe, development of new drugs, and adequate government reimbursement policies have also fueled the growth of MDD treatment market.
However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of MDD drugs may hinder the growth of MDD treatment market over the forecasted period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
At present, antidepressants are most commonly used drugs for the treatment of MDD, and has the largest market segment. Major brands of SSRI’s include Citalopram, Escitalopram, Fluoxetine, Paroxetine, and Sertraline. Bupropion, Mirtazapine, and Razodone, are atypical antidepressants frequently used for the treatment of MDD.
Major brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine, Ziprasidone, and Aripiprazole. Global MDD treatment market is expected to grow with a healthy CAGR owing to increase in MDD patient pool over the forecast period.
Geographically, North America market is estimated to hold maximum market revenue share in global MDD treatment market owing to increase in number of patients suffering from MDD, and advancement in technology to develop new therapeutic drugs and followed by Europe and Asia-Pacific respectivily.
The market in Asia-Pacific is expected to expand at a significant CAGR over the forecasted period due to increasing awareness for depression conditions and complications associated with it. MDD treatment market is expected to register healthier CAGR in emerging markets such as India, China, and Brazil compared to other developed regions in the world.
Key companies operational in MDD treatment market are Eli Lilly and Company, Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Published : July 2023
Published : January 2023
Published : August 2022
Published : September 2021